The start-up Dextrain is launching an innovative medical device to help patients regain the dexterity of their hands after a stroke.
In France, 160,000 people suffer from a stroke each year and more than 500,000 French people are currently living with after-effects. It is the leading cause of acquired disability in adults. Up to half of stroke survivors suffer from reduced hand and finger function. This deficit limits patients' autonomy in their daily activities and strongly impacts their quality of life.
This is why researcher Pavel Lindberg's team is launching the Dextrain Manipulandum, a medical device designed to improve the independence and quality of life of these stroke patients.
This innovation, available today, is the result of more than 15 years of clinical experience and neuroscience research. It is the result of a research program conducted at the Paris Institute of Psychiatry and Neuroscience (Inserm, Université de Paris) and of support from Erganeo since 2012, including the maturation of the project associated with several patent applications. The team then partnered with Archos for the industrialization and marketing.
"We are delighted with this first co-creation with Archos of a very promising start-up in the medical device sector. The Erganeo-Archos partnership is an ideal association between a technology transfer player and an established industrialist for the market access of these technologies," said Suat Topsu, president of Erganeo.
"For our project, the association between Erganeo, Dextrain and Archos allowed us to go all the way", says Loïc Poirier, CEO of Dextrain.